EMAIL THIS PAGE TO A FRIEND

Journal of proteomics

Quantitative proteomic analysis of paired colorectal cancer and non-tumorigenic tissues reveals signature proteins and perturbed pathways involved in CRC progression and metastasis.


PMID 26054784

Abstract

Modern proteomics has proven instrumental in our understanding of the molecular deregulations associated with the development and progression of cancer. Herein, we profile membrane-enriched proteome of tumor and adjacent normal tissues from eight CRC patients using label-free nanoLC-MS/MS-based quantitative proteomics and advanced pathway analysis. Of the 948 identified proteins, 184 proteins were differentially expressed (P<0.05, fold change>1.5) between the tumor and non-tumor tissue (69 up-regulated and 115 down-regulated in tumor tissues). The CRC tumor and non-tumor tissues clustered tightly in separate groups using hierarchical cluster analysis of the differentially expressed proteins, indicating a strong CRC-association of this proteome subset. Specifically, cancer associated proteins such as FN1, TNC, DEFA1, ITGB2, MLEC, CDH17, EZR and pathways including actin cytoskeleton and RhoGDI signaling were deregulated. Stage-specific proteome signatures were identified including up-regulated ribosomal proteins and down-regulated annexin proteins in early stage CRC. Finally, EGFR(+) CRC tissues showed an EGFR-dependent down-regulation of cell adhesion molecules, relative to EGFR(-) tissues. Taken together, this study provides a detailed map of the altered proteome and associated protein pathways in CRC, which enhances our mechanistic understanding of CRC biology and opens avenues for a knowledge-driven search for candidate CRC protein markers.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

I2886
3-Indoleacetic acid, plant cell culture tested, crystalline
C10H9NO2
I3750
3-Indoleacetic acid, 98%
C10H9NO2
I5148
Indole-3-acetic acid sodium salt, BioReagent, plant cell culture tested, ≥98%
C10H8NNaO2
295531
Methylamine, anhydrous, ≥98%
CH5N
534102
Methylamine solution, 33 wt. % in absolute ethanol
CH5N
426466
Methylamine solution, 40 wt. % in H2O
CH5N
395048
Methylamine solution, 2.0 M in methanol
CH5N
395056
Methylamine solution, 2.0 M in THF
CH5N
T1378
Sigma 7-9®, ≥99% (titration), crystalline
C4H11NO3
154563
Tris(hydroxymethyl)aminomethane, ultrapure grade, ≥99.9%
C4H11NO3
252859
Tris(hydroxymethyl)aminomethane, ACS reagent, ≥99.8%
C4H11NO3
X114
Triton X-114, laboratory grade
RDD008
Trizma® base, anhydrous, free-flowing, Redi-Dri, ≥99.9%
C4H11NO3
T1503
Trizma® base, Primary Standard and Buffer, ≥99.9% (titration), crystalline
C4H11NO3
T6066
Trizma® base, BioPerformance Certified, meets EP, USP testing specifications, cell culture tested, ≥99.9% (titration)
C4H11NO3
T6791
Trizma® base, BioXtra, pH 10.5-12.0 (1 M in H2O), ≥99.9% (titration)
C4H11NO3
T4661
Trizma® base, ≥99.9% (titration), crystalline
C4H11NO3
93362
Trizma® base, BioUltra, for molecular biology, ≥99.8% (T)
C4H11NO3
93352
Trizma® base, ≥99.0% (T)
C4H11NO3
93350
Trizma® base, puriss. p.a., ≥99.7% (T)
C4H11NO3
33742
Trizma® base, puriss. p.a., buffer substance, ≥99.5%
C4H11NO3
T6687
Tromethamine, meets USP testing specifications
C4H11NO3
RES3137T-A7
Tromethamine, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production., suitable for cell culture, meets USP testing specifications
C4H11NO3
RES3193T-A7
Tromethamine, PharmaGrade, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production, suitable for cell culture, Meets USP, EP, JPC, BP testing specifications.
C4H11NO3